Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections
ABSTRACT In recent years, bacteriophages (or phages) have reentered the spotlight as alternative or adjuvant therapeutic agents to antibiotics. Their efficacy in more recalcitrant forms of infections like biofilms, frequently encountered in the orthopedic setting, remains less characterized. The pre...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2024-01-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.03219-23 |
| _version_ | 1797357437431316480 |
|---|---|
| author | Steven De Soir Hortence Parée Nur Hidayatul Nazirah Kamarudin Jeroen Wagemans Rob Lavigne Annabel Braem Maya Merabishvili Daniel De Vos Jean-Paul Pirnay Françoise Van Bambeke |
| author_facet | Steven De Soir Hortence Parée Nur Hidayatul Nazirah Kamarudin Jeroen Wagemans Rob Lavigne Annabel Braem Maya Merabishvili Daniel De Vos Jean-Paul Pirnay Françoise Van Bambeke |
| author_sort | Steven De Soir |
| collection | DOAJ |
| description | ABSTRACT In recent years, bacteriophages (or phages) have reentered the spotlight as alternative or adjuvant therapeutic agents to antibiotics. Their efficacy in more recalcitrant forms of infections like biofilms, frequently encountered in the orthopedic setting, remains less characterized. The present study aimed at evaluating the activity of phage-antibiotic combinations against Pseudomonas aeruginosa biofilms. A large collection of phages was de novo isolated from a wide variety of environmental sources. Three phages with a large host range against a.o. clinical orthopedic isolates, PSP2 (Yuavirus), PSP3 (Pbunavirus), and PSP30 (Bruynoghevirus), were selected for phage-antibiotic synergy assays on mature P. aeruginosa PAO1 biofilms. Phages were combined with ciprofloxacin, meropenem, and ceftazidime, all used as standard of care in bone-related infections. Significant reductions in both cell counts and biomass were observed for all phage-antibiotic combinations. The highest reduction in viable cell counts was observed for PSP3 and PSP2 in combination with ceftazidime [4.58 and 4.30 log10 Colony Forming Units (CFU)/well], followed by all phage combinations with ciprofloxacin (up to 3.56 log10 CFU/well). The highest reduction in biomass was obtained by combining PSP3 with ciprofloxacin (29.8%). Metabolic assays confirmed these findings with reductions in biofilm respiratory rate of up to 65%. Scanning electron microscopy imaging of PAO1 biofilms grown on titanium coupons and treated by ciprofloxacin and PSP30 confirmed the efficacy of the combined treatment with PSP30 and ciprofloxacin. This study highlights the synergetic effects of phage-antibiotic combinations on P. aeruginosa biofilms, thereby offering a promising approach to combat biofilm-associated infections. IMPORTANCE Biofilm-related infections are among the most difficult-to-treat infections in all fields of medicine due to their antibiotic tolerance and persistent character. In the field of orthopedics, these biofilms often lead to therapeutic failure of medical implantable devices and urgently need novel treatment strategies. This forthcoming article aims to explore the dynamic interplay between newly isolated bacteriophages and routinely used antibiotics and clearly indicates synergetic patterns when used as a dual treatment modality. Biofilms were drastically more reduced when both active agents were combined, thereby providing additional evidence that phage-antibiotic combinations lead to synergism and could potentially improve clinical outcome for affected patients. |
| first_indexed | 2024-03-08T14:44:00Z |
| format | Article |
| id | doaj.art-7361fd48e6244f60a5c6b612b7d4bc7a |
| institution | Directory Open Access Journal |
| issn | 2165-0497 |
| language | English |
| last_indexed | 2024-03-08T14:44:00Z |
| publishDate | 2024-01-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj.art-7361fd48e6244f60a5c6b612b7d4bc7a2024-01-11T14:04:37ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972024-01-0112110.1128/spectrum.03219-23Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infectionsSteven De Soir0Hortence Parée1Nur Hidayatul Nazirah Kamarudin2Jeroen Wagemans3Rob Lavigne4Annabel Braem5Maya Merabishvili6Daniel De Vos7Jean-Paul Pirnay8Françoise Van Bambeke9Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain , Brussels, BelgiumPharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain , Brussels, BelgiumDepartment of Materials Engineering, Biomaterials and Tissue Engineering Research Group, KU Leuven , Leuven, BelgiumLaboratory of Gene Technology, KU Leuven , Leuven, BelgiumLaboratory of Gene Technology, KU Leuven , Leuven, BelgiumDepartment of Materials Engineering, Biomaterials and Tissue Engineering Research Group, KU Leuven , Leuven, BelgiumLaboratory for Molecular and Cellular Technology (LabMCT), Queen Astrid Military Hospital , Neder-over-Heembeek, BelgiumLaboratory for Molecular and Cellular Technology (LabMCT), Queen Astrid Military Hospital , Neder-over-Heembeek, BelgiumLaboratory for Molecular and Cellular Technology (LabMCT), Queen Astrid Military Hospital , Neder-over-Heembeek, BelgiumPharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain , Brussels, BelgiumABSTRACT In recent years, bacteriophages (or phages) have reentered the spotlight as alternative or adjuvant therapeutic agents to antibiotics. Their efficacy in more recalcitrant forms of infections like biofilms, frequently encountered in the orthopedic setting, remains less characterized. The present study aimed at evaluating the activity of phage-antibiotic combinations against Pseudomonas aeruginosa biofilms. A large collection of phages was de novo isolated from a wide variety of environmental sources. Three phages with a large host range against a.o. clinical orthopedic isolates, PSP2 (Yuavirus), PSP3 (Pbunavirus), and PSP30 (Bruynoghevirus), were selected for phage-antibiotic synergy assays on mature P. aeruginosa PAO1 biofilms. Phages were combined with ciprofloxacin, meropenem, and ceftazidime, all used as standard of care in bone-related infections. Significant reductions in both cell counts and biomass were observed for all phage-antibiotic combinations. The highest reduction in viable cell counts was observed for PSP3 and PSP2 in combination with ceftazidime [4.58 and 4.30 log10 Colony Forming Units (CFU)/well], followed by all phage combinations with ciprofloxacin (up to 3.56 log10 CFU/well). The highest reduction in biomass was obtained by combining PSP3 with ciprofloxacin (29.8%). Metabolic assays confirmed these findings with reductions in biofilm respiratory rate of up to 65%. Scanning electron microscopy imaging of PAO1 biofilms grown on titanium coupons and treated by ciprofloxacin and PSP30 confirmed the efficacy of the combined treatment with PSP30 and ciprofloxacin. This study highlights the synergetic effects of phage-antibiotic combinations on P. aeruginosa biofilms, thereby offering a promising approach to combat biofilm-associated infections. IMPORTANCE Biofilm-related infections are among the most difficult-to-treat infections in all fields of medicine due to their antibiotic tolerance and persistent character. In the field of orthopedics, these biofilms often lead to therapeutic failure of medical implantable devices and urgently need novel treatment strategies. This forthcoming article aims to explore the dynamic interplay between newly isolated bacteriophages and routinely used antibiotics and clearly indicates synergetic patterns when used as a dual treatment modality. Biofilms were drastically more reduced when both active agents were combined, thereby providing additional evidence that phage-antibiotic combinations lead to synergism and could potentially improve clinical outcome for affected patients.https://journals.asm.org/doi/10.1128/spectrum.03219-23bacteriophage therapyantibioticsPseudomonas aeruginosabiofilms |
| spellingShingle | Steven De Soir Hortence Parée Nur Hidayatul Nazirah Kamarudin Jeroen Wagemans Rob Lavigne Annabel Braem Maya Merabishvili Daniel De Vos Jean-Paul Pirnay Françoise Van Bambeke Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections Microbiology Spectrum bacteriophage therapy antibiotics Pseudomonas aeruginosa biofilms |
| title | Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections |
| title_full | Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections |
| title_fullStr | Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections |
| title_full_unstemmed | Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections |
| title_short | Exploiting phage-antibiotic synergies to disrupt Pseudomonas aeruginosa PAO1 biofilms in the context of orthopedic infections |
| title_sort | exploiting phage antibiotic synergies to disrupt pseudomonas aeruginosa pao1 biofilms in the context of orthopedic infections |
| topic | bacteriophage therapy antibiotics Pseudomonas aeruginosa biofilms |
| url | https://journals.asm.org/doi/10.1128/spectrum.03219-23 |
| work_keys_str_mv | AT stevendesoir exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT hortenceparee exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT nurhidayatulnazirahkamarudin exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT jeroenwagemans exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT roblavigne exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT annabelbraem exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT mayamerabishvili exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT danieldevos exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT jeanpaulpirnay exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections AT francoisevanbambeke exploitingphageantibioticsynergiestodisruptpseudomonasaeruginosapao1biofilmsinthecontextoforthopedicinfections |